肝窦阻塞综合征的研究进展

张明

doi:10.12449/JCH240104

肝窦阻塞综合征的研究进展

DOI: 10.12449/JCH240104

张明^, ,

南京大学医学院附属鼓楼医院消化内科，南京 210008

利益冲突声明：本文不存在任何利益冲突。

详细信息

通信作者:
张明， mg0923@163.com （ORCID： 0009-0009-7742-3128）

计量
- 文章访问数: 1037
- HTML全文浏览量: 177
- PDF下载量: 218
- 被引次数: 0
出版历程
- 收稿日期: 2023-12-11
- 录用日期: 2023-12-20
- 出版日期: 2024-01-23

Research advances in hepatic sinusoidal obstruction syndrome

Ming ZHANG^{,
,}

Department of Gastroenterology，Affiliated Drum Tower Hospital of Nanjing University Medical School，Nanjing 210008，China

More Information

Corresponding author: ZHANG Ming， mg0923@163.com （ORCID： 0009-0009-7742-3128）

摘要

摘要: 肝窦阻塞综合征（HSOS）也被称为肝小静脉闭塞病，是一类由各种原因导致的肝血窦阻塞和肝小静脉闭塞纤维化的肝脏血管性疾病。本文系统阐述了HSOS的认识过程和命名演变、病因和发病机制、临床表现、诊断与鉴别诊断、预防和治疗等方面的研究进展。HSOS可发生于接受骨髓造血干细胞移植清髓处理、放射/化学治疗和摄入含吡咯生物碱药物的人群，常见临床表现为腹胀、肝区胀痛、腹水、黄疸、肝大等。针对不同病因，HSOS的诊断标准也不相同，需要与其他药物性肝病、肝静脉流出道梗阻等疾病相鉴别。去纤苷和低分子肝素分别对造血干细胞和吡咯生物碱相关的HSOS具有治疗作用，奥沙利铂化疗导致的HSOS目前尚无有效治疗药物。
- 肝窦阻塞综合征 /
- 造血干细胞移植 /
- 奥沙利铂
Abstract: Hepatic sinusoidal obstruction syndrome （HSOS）， also known as hepatic veno-occlusive disease， is hepatic vascular disease of hepatic sinusoidal obstruction and hepatic venular occlusion and fibrosis due to various causes. This article systematically elaborates on the research advances in HSOS from the aspects of understanding and naming， etiology and pathogenesis， clinical manifestation， diagnosis and differential diagnosis， prevention， and treatment. HSOS can occur in patients receiving bone marrow hematopoietic stem cell transplantation， radiotherapy/chemotherapy， and medication containing pyrrolidine alkaloids， and the common clinical manifestations of HSOS include abdominal distension， distending pain in the liver area， ascites， jaundice， and hepatomegaly. The diagnostic criteria for HSOS vary with etiology， and it needs to be differentiated from other diseases such as drug-induced liver diseases and hepatic venous outflow tract obstruction. Defibrotide and low-molecular-weight heparin have a therapeutic effect on HSOS associated with hematopoietic stem cells and pyrrolidine alkaloids， respectively， and there are currently no effective drugs for HSOS caused by oxaliplatin chemotherapy.
- Hepatic Sinus Obstruction Syndrome /
- Hematopoietic Stem Cell Transplantation /
- Oxaliplatin

HTML全文

百舸争流，奋楫者先。2023年，《临床肝胆病杂志》12期重点号专刊权威引领，树立学科发展风向标，奏响学术前沿最强音；创办“柳荫医学峰会”“柳芽医学论坛”“柳荫访谈”系列活动，打造我国医学学术活动品牌新IP；获准加入国际管理与技术编辑学会（ISMTE）和国际医学期刊编辑委员会（ICMJE），接轨国际学术出版规范之路取得新突破；数字出版矩阵建设从“相融”迈向“深融”，实现全媒体、全形态、全流程传播体系高速发展，官方网站年度访问量超236万次，21个新媒体平台年度受众超3 000万人次，79场学术直播参会观众超100万人。

笃行不怠，勇毅者胜。2023年，《临床肝胆病杂志》继续入编《中文核心期刊要目总览》；被荷兰《医学文摘（网络版）》（Embase）、ISSN国际中心开放学术资源库（ROAD）收录，稳居我国中文科技期刊进入国际知名数据库数量榜首；荣获“第四届吉林省高校科技期刊奖·卓越奖”；13篇论文入选中国科协“2023年度科技期刊双语传播工程”；2篇论文获评中华医学会“2023年度中华医学科技论文TOP100”；1篇论文荣膺中国科协“第八届优秀科技论文”，连续2届蝉联该奖项；在《科技期刊世界影响力指数（WJCI）报告》“消化病及腹部疾病”目录仅入选的8种中文期刊中排名四连冠；连续3届入选“中国精品科技期刊”，F5000论文入选总数（64篇）连续6年高居消化病学类精品科技期刊榜首；综合评价总分在我国消化病学类核心期刊中排名五连冠；近5年来第4次问鼎“百种中国杰出学术期刊”！

2023次列车已到站，2024号巨轮正启航。《临床肝胆病杂志》将继续凝专业之力，聚奋进之魂，夯学术之基，在新兴智能化信息革命中勇立潮头，以精品意识、精良内容、精准服务，助力我国肝胆病学科再创佳绩，更展新风！

岁且更始，时乃日新。恭祝大家新春嘉平！葳蕤繁祉！长乐未央！

《临床肝胆病杂志》主编

2024年元月

参考文献(28)

[1]	VALLA DC, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40( 4): 378- 385. DOI: 10.1016/j.clinre.2016.01.006.
[2]	FAN CQ, CRAWFORD JM. Sinusoidal obstruction syndrome(hepatic veno-occlusive disease)[J]. J Clin Exp Hepatol, 2014, 4( 4): 332- 346. DOI: 10.1016/j.jceh.2014.10.002.
[3]	Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome(2017, Nanjing)[J]. J Clin Hepatol, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003. 中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33( 9): 1627- 1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003.
[4]	ZHUGE YZ, LIU YL, XIE WF, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34( 4): 634- 642. DOI: 10.1111/jgh.14612.
[5]	BRAS G, JELLIFFE DB, STUART KL. Veno-occlusive disease of liver with nonportal type of cirrhosis, occurring in Jamaica[J]. AMA Arch Pathol, 1954, 57( 4): 285- 300.
[6]	RUBBIA-BRANDT L, AUDARD V, SARTORETTI P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer[J]. Ann Oncol, 2004, 15( 3): 460- 466. DOI: 10.1093/annonc/mdh095.
[7]	ZHU C, REN XH, LIU D, et al. Oxaliplatin-induced hepatic sinusoidal obstruction syndrome[J]. Toxicology, 2021, 460: 152882. DOI: 10.1016/j.tox.2021.152882.
[8]	CORBACIOGLU S, GRUPP SA, RICHARDSON PG, et al. Prevention of veno-occlusive disease/sinusoidal obstruction syndrome: A never-ending story and no easy answer[J]. Bone Marrow Transplant, 2023, 58( 8): 839- 841. DOI: 10.1038/s41409-023-02007-2.
[9]	de LÉDINGHEN V, VILLATE A, ROBIN M, et al. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2020, 44( 4): 480- 485. DOI: 10.1016/j.clinre.2020.03.019.
[10]	MA YX, FENG YL, WU YY, et al. Toxic pyrrolizidine alkaloids in Chinese herbal medicine: Control status and advances in analytical method[J]. Chin Tradit Herb Drugs, 2021, 52( 24): 7645- 7657. DOI: 10.7501/j.issn.0253-2670.2021.24.028. 马跃新, 冯有龙, 吴嫣艳, 等. 中草药中毒性吡咯里西啶类生物碱分析方法研究进展及控制现状[J]. 中草药, 2021, 52( 24): 7645- 7657. DOI: 10.7501/j.issn.0253-2670.2021.24.028.
[11]	ÖZKAN HA, ÖZKAN SG. Hepatic veno-occlusive disease(sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation in adult patients: Diagnosis, incidence, prophylaxis, and treatment[J]. Transfus Apher Sci, 2022, 61( 1): 103372. DOI: 10.1016/j.transci.2022.103372.
[12]	MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51( 7): 906- 912. DOI: 10.1038/bmt.2016.130.
[13]	WAESPE N, STREBEL S, JURKOVIC MLAKAR S, et al. Genetic predictors for sinusoidal obstruction syndrome-a systematic review[J]. J Pers Med, 2021, 11( 5): 347. DOI: 10.3390/jpm11050347.
[14]	KUMAR A, PALEK R, LISKA V. A critical analysis of experimental animal models of sinusoidal obstruction syndrome[J]. J Clin Exp Hepatol, 2019, 9( 3): 345- 353. DOI: 10.1016/j.jceh.2018.07.002.
[15]	TODA R, SEO S, UEMOTO Y, et al. Clinically relevant model of oxaliplatin-induced sinusoidal obstruction syndrome[J]. Hepatol Res, 2023, 53( 2): 145- 159. DOI: 10.1111/hepr.13842.
[16]	CALISTRI L, RASTRELLI V, NARDI C, et al. Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis[J]. World J Gastroenterol, 2021, 27( 46): 7866- 7893. DOI: 10.3748/wjg.v27.i46.7866.
[17]	LIU L, ZHANG W, ZHUGE YZ. Review on diagnostic criteria of hepatic sinusoidal obstruction syndrome[J]. Chin J Hepatol, 2020, 28( 12): 1064- 1068. DOI: 10.3760/cma.j.cn501113-20190415-00124. 刘璐, 张玮, 诸葛宇征. 肝窦阻塞综合征诊断标准综述[J]. 中华肝脏病杂志, 2020, 28( 12): 1064- 1068. DOI: 10.3760/cma.j.cn501113-20190415-00124.
[18]	CHAO N. How I treat sinusoidal obstruction syndrome[J]. Blood, 2014, 123( 26): 4023- 4026. DOI: 10.1182/blood-2014-03-551630.
[19]	CORBACIOGLU S. Sinusoidal obstruction syndrome(SOS) and defibrotide: We are not there yet[J]. Transplant Cell Ther, 2023, 29( 5): 287- 288. DOI: 10.1016/j.jtct.2023.03.032.
[20]	COLECCHIA A, RAVAIOLI F, SESSA M, et al. Liver stiffness measurement allows early diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome in adult patients who undergo hematopoietic stem cell transplantation: Results from a monocentric prospective study[J]. Biol Blood Marrow Transplant, 2019, 25( 5): 995- 1003. DOI: 10.1016/j.bbmt.2019.01.019.
[21]	ZHANG W, LIU L, ZHANG M, et al. Validation of the Nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome[J]. J Clin Transl Hepatol, 2021, 9( 3): 345- 352. DOI: 10.14218/JCTH.2020.00124.
[22]	CUTLER C, KIM HT, AYANIAN S, et al. Prediction of veno-occlusive disease using biomarkers of endothelial injury[J]. Biol Blood Marrow Transplant, 2010, 16( 8): 1180- 1185. DOI: 10.1016/j.bbmt.2010.02.016.
[23]	TONG YR, ZHANG M, QI ZX, et al. Hepatic venous occlusion type of budd-chiari syndrome versus pyrrolizidine alkaloid-induced hepatic sinusoidal obstructive syndrome: A multi-center retrospective study[J]. J Pers Med, 2023, 13( 4): 603. DOI: 10.3390/jpm13040603.
[24]	PENG C, ZHANG X, ZHANG F, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: a retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol, 2020, 32( 9): 1168- 1178. DOI: 10.1097/MEG.0000000000001630.
[25]	WU F, YU JA, GAN HY, et al. Timing and efficacy of transjugular intrahepatic portosystemic shunt in patients with pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Sci Rep, 2021, 11: 21743. DOI: 10.1038/s41598-021-01201-w.
[26]	WANG X, ZHANG W, ZHANG M, et al. Development of a Drum Tower Severity Scoring(DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. Hepatol Int, 2022, 16( 3): 669- 679. DOI: 10.1007/s12072-021-10293-5.
[27]	XIAO J, TU J, ZHANG H, et al. Risk factors of poor prognosis in patients with pyrrolidine alkaloid-induced hepatic sinusoidal obstruction syndrome after transjugular intrahepatic portosystemic shunt[J]. Hepatol Int, 2021, 15( 3): 720- 729. DOI: 10.1007/s12072-020-10126-x.
[28]	RUUTU T, JUVONEN E, REMBERGER M, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: Long-term follow-up of a randomized study[J]. Biol Blood Marrow Transplant, 2014, 20( 1): 135- 138. DOI: 10.1016/j.bbmt.2013.10.014.